share_log

Earnings Call Summary | MEDICINE MAN TECHNOLOGIES INC(SHWZ.US) Q2 2024 Earnings Conference

Earnings Call Summary | MEDICINE MAN TECHNOLOGIES INC(SHWZ.US) Q2 2024 Earnings Conference

業績會總結 | MEDICINE MAN TECHNOLOGIES INC(SHWZ.US) 2024財年第二季度業績會
moomoo AI ·  08/14 08:04  · 電話會議

The following is a summary of the Medicine Man Technologies, Inc. (SHWZ) Q2 2024 Earnings Call Transcript:

以下是Medicine Man Technologies, Inc.(SHWZ)2024年第二季度業績會實錄摘要:

Financial Performance:

金融業績:

  • Reported Q2 2024 total revenue of $43.2 million, marking a 2% increase.

  • Gross profit was $19 million, equating to 44% of total revenue, a decrease from 54% year-over-year primarily due to pricing pressure and increased third-party purchasing.

  • Operating loss was $2.7 million, with adjusted EBITDA at $9 million or 21% of revenue. Last year, EBITDA was 33% of revenue.

  • Cash and cash equivalents stood at $12.3 million, with total debt at $163.4 million as of June 30, 2024.

  • 報告2024年第二季度總營業收入爲4320萬美元,增長2%。

  • 毛利潤爲1900萬美元,佔總營業收入的44%,同比下降10個百分點,主要是由於定價壓力和第三方採購的增加導致。

  • 運營虧損爲270萬美元,調整後EBITDA爲900萬美元,佔營業收入的21%。去年EBITDA佔營業收入的比例爲33%。

  • 截至2024年6月30日,現金及現金等價物爲1230萬美元,總債務爲1.634億美元。

Business Progress:

業務進展:

  • Closed three underperforming dispensaries and a distribution center in Colorado to prioritize core operations.

  • Opened a new medical and recreational dispensary in Bernalillo, New Mexico, under the Our Greenleaf banner, bringing the total to 35 dispensaries.

  • Implemented new LED lighting in cultivation facilities aimed at a double-digit yield improvement.

  • Announced debt restructuring to extend maturities for financial flexibility.

  • 關閉了科羅拉多州的三個表現不佳的零售店和一個配送中心,以優先考慮核心業務。

  • 在新墨西哥州伯納利洛,以「我們的綠葉」(Our Greenleaf)的品牌開設了一家新的醫療和娛樂購物中心,使總門店數達到35家。

  • 在種植設施中使用了新的LED照明,旨在提高兩位數的產量。

  • 宣佈債務重組,以延長到期日以實現財務靈活性。

Opportunities:

機會:

  • Plans to refine retail strategy and drive further operating efficiencies across retail, cultivation, and manufacturing operations.

  • Positioned for growth and stronger profitability in the second half of 2024 through ongoing operational optimizations and new product introductions.

  • 計劃完善零售策略,並在零售、種植和製造業務方面推動進一步的營運效率。

  • 通過持續的運營優化和新產品推出,定位於2024年下半年的增長和更強的盈利能力。

Risks:

風險:

  • Anticipates net new store growth shifting from positive to negative in the latter half of the year due to regulatory actions increasing enforcement and accelerating compliance checks resulting in numerous closures.

  • 預計由於監管行動加強,加速合規檢查導致數次關閉,淨新店增長將從正變負。

More details: MEDICINE MAN TECHNOLOGIES INC IR

更多細節請參見MEDICINE MAN TECHNOLOGIES INC IR。

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息,請參閱IR網站。本文只是爲投資者提供參考,沒有任何指導或推薦建議。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論